. 2007 Apr 3;96(8):1183–1190. doi: 10.1038/sj.bjc.6603719

Table 6. Included studies – chemotherapy vs chemoradiotherapy, followed by chemotherapy.

Authors	Group (number randomised)	Median age and gender	Chemotherapy/radiotherapy used and dose
Hazel et al (1981)	Chemo (n=15)	NA	5FU 500 mg m⁻² weekly, methyl CCNU 100 mg m⁻² every 6 weeks
	Combin rx (n=15)	NA	5FU 500 mg m⁻² weekly, radiotherapy 4600 rad in 4.5 weeks. After completion of chemoradiation, methyl CCNU added
Klassen et al (1985)	chemo (n=44)	NA; 31 men, 13 women	5FU 600 mg m⁻² weekly
	Combin rx (n=47)	NA; 22 men, 25 women	5FU 600 mg m⁻² on first days of radiotherapy 4000 rad radiotherapy over 4 weeks After completion of chemoradiation, 5FU 600 mg m⁻² weekly
GITSG (1988)	Chemo (n=21)	60 years; 13 men, 8 women	5FU 600 mg m⁻² on days 1, 8, 29, 36, streptozocin 1 g m⁻² every 8 weeks, mitomycin 10 mg m⁻² on day 1 every 8 weeks
	Combin rx (n=22)	61 years; 14 men, 8 women	Radiotherapy 5400 rad over 6 weeks with 5FU 350 mg m⁻² on first 3 days and last 3 days of radiotherapy. After completion of chemoradiation, chemo-SMF regimen: 5FU 600 mg m⁻², streptozocin 1 g m⁻² on days 1, 8, 29, 36 every 8 weeks, mitomycin 5 mg m⁻² at first dose, then 10 mg m⁻² every 8 weeks
Chauffert et al (2006)	Chemotherapy (n=60)	Mean age=60.1 years	Gemcitabine 1000 mg m⁻² 7q8 weeks initially, then 3q4 weeks
	Combination rx (n=59)	Mean age=62.7 years	60 Gy in 6 weeks, with 5FU 300 mg m⁻² 24 h⁻¹ on days 1–5 every week and cisplatin 20 mg m⁻² day⁻¹ on days 1–5 at week 1 and 5. After completion of chemoradiation, gemcitabine 1000 mg m⁻² 3q4 weeks

C, CCNU=lomustine; chemo=chemotherapy; Combin rx=combination therapy (chemoradiotherapy, followed by chemotherapy); MMC=mitomycin; NA=data not available.